About F-star Biotechnology Ltd

F-star, an invoX company, is a clinical-stage biopharmaceutical business pioneering bispecific antibodies in immunotherapy so more people with cancer can live longer and improved lives. F-star is committed to working towards a future free from cancer and other serious diseases through the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in treatments. F-star has four second-generation immunooncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate, with over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several areas, including oncology, immunology, and CNS.

website icon
Website
employees icon
Employees
industry icon
Industry
Biotechnology
location icon
Headquarter
Babraham Research Campus, Cambridge, Cambridgeshire CB22 3AT, GB
description icon
Keywords
Oncology, Biotech, Cancer Research, Immuno-Oncology, Cancer, Cns, Immunology, Bispecific Antibodies, Immmunotherapy, Tetravalent Bispecifics

F-star Biotechnology Ltd Alternatives

Industry
biotechnology
Industry
Biotechnology
Industry
biotechnology
Industry
biotechnology
Industry
biotechnology
Industry
biotechnology

Frequently Asked Questions about F-star Biotechnology Ltd

Who are the decision makers in F-star Therapeutics, Inc.?

The decision makers in F-star Therapeutics, Inc. are Rosaleen Mcneill, Rosie Almond - Assoc Cipd, Ryan Fiehler, etc. Click to Find F-star Therapeutics, Inc. decision makers emails.

Supercharge your
Prospecting &
Outreach with
ContactOut

Search Portal

Find countless prospects outside of LinkedIn fast

Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.

Discover the source of our data

Learn more